BULLETIN DE L'INSTITUT PASTEUR

1995 — vol. 93

SOMMAIRE/CONTENTS

Synthesis of particulate structures as bluetongue virus vaccine and their use as multiple immunogen delivery systems, **P. Roy**

Synthèse de particules vaccinales de type virus "bluetongue" et application aux systèmes de transport des immunogènes 3

Controversies surrounding current therapies for sepsis syndrome, **J.-M. Cavaillon**

Controverses entourant les approches thérapeutiques actuelles du syndrome septique 21

Platelet-activating factor and human blood monocytes: an overview, **Y. Denizot, F. Dupuis and V. Praloran**

PAF et monocytes sanguins humains 43

The Spirochaetes: a different way of life, **G. Baranton and I.G. Old**

Le monde des Spirochètes 63

Les BIMEs: un exemple de séquences répétées chez les entérobactéries, **S. Bachellier**

BIME sequences: an example of enterobacterial repetitive sequences 97

Il y a 100 ans...

A propos de l'article de Jules Bordet «Les leucocytes et les propriétés actives du sérum chez les vaccinés» (découverte de la voie classique de l'activation du complément) paru dans les Annales de l'Institut Pasteur en juin 1895, **G. Bordenave** 159

Signals in plant disease resistance, **D.A. Dempsey and D.F. Klessig**

Signaux pour la résistance en phytopathologie 167

Les mécanismes du contrôle des échanges génétiques interspécifiques et de la variabilité génétique chez les bactéries, **I. Matic**

The control of interspecies genetic exchanges and genetic variability in bacteria 187

2nd Forum in the Bulletin de l'Institut Pasteur

"Cholera vaccines" organized by **J.-M. Fournier and R.M. Fauve**

Introduction: **R.M. Fauve and J.-M. Fournier** 227

Underestimating the cholera problem and the potential for vaccination — a case for accelerating the use of cholera vaccines, **D.A. Sack** 229

Selection of outcomes for assessing vaccine protection in cholera vaccine trials: the need for suitable breadth and depth, **J. Clemens, M. Rao and A. Naficy** 237

Live oral cholera vaccine: from principle to product, **M.M. Levine and J.B. Kaper** 243

Live cholera vaccines: perspectives on their construction and safety, **J.J. Mekalanos, M.K. Waldor, C.L. Gardel, T.S. Coster, J. Kenner, K.P. Killeen, D.T. Beattie, A. Trofa, D.N. Taylor and J.C. Sadoff** 255

A beginning to cell surface studies in *Vibrio cholerae*: a personal perspective, **P.A. Manning** 263

Development of O-specific polysaccharide-protein conjugates is based upon the protective effect of serum vibriocidal antibodies against cholera, **S.C. Szu, R. Gupta, P. Kovac, D.N. Taylor and J.B. Robbins** 269

Protective activities of serum immunoglobulin G on the mucosal surface to *Vibrio cholerae* O1, **F. Bougoudogo, F. Vely, F. Nato, A. Boutonnier, P. Gounon, J.-C. Mazié and J.-M. Fournier** 273

Capsular polysaccharide-protein conjugate vaccines against *Vibrio cholerae* O139 Bengal, **J.A. Johnson, A. Joseph and J.G. Morris, Jr.** 285

Chromosomal rearrangement in *Vibrio cholerae* O139, **S. Dumontier, V. Escuyer, E. Abachin, J.-M. Fournier and P. Berche** 291